Summary
Andrew Kalenkiewicz is an MD/PhD student in the Medical Scientist Training Program at the University of Iowa with 11 years of hands-on experience in structural biology, biophysics, and computer-aided drug design. He blends dry‑lab computational approaches (virtual screening, docking, molecular dynamics) with wet‑lab biophysical validation, cultivated through internships and research at NIH, Genentech, Amgen, and the University of Michigan. His work includes designing novel inhibitors for Bcl-2 family proteins and identifying lead compounds against protozoan parasites, demonstrating a strong facility for statistical programming and thermodynamic integration. Andrew also co-founded a med‑tech startup focused on minimally invasive intravascular devices, bringing translational engineering and entrepreneurial experience to his scientific training. Based in Iowa City, he combines deep technical rigor with practical drug‑discovery insight and has repeatedly revealed nonobvious protein dynamics through long-timescale simulations.
11 years of coding experience
3 years of employment as a software developer
Master of Science (M.S.E.), Biomedical Engineering (Biotechnology Concentration), Master of Science (M.S.E.), Biomedical Engineering (Biotechnology Concentration) at University of Michigan
Doctor of Medicine - MD, Doctor of Medicine - MD at University of Iowa